A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
08
02
2022
accepted:
05
07
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Biomaterial-associated infections are a major healthcare challenge as they are responsible for high disease burden in critically ill patients. In this study, we have developed drug-eluting antibacterial catheters to prevent catheter-related infections. Niclosamide (NIC), originally an antiparasitic drug, was incorporated into the polymeric matrix of thermoplastic polyurethane (TPU) via solvent casting, and catheters were fabricated using hot-melt extrusion technology. The mechanical and physicochemical properties of TPU polymers loaded with NIC were studied. NIC was released in a sustained manner from the catheters and exhibited in vitro antibacterial activity against Staphylococcus aureus and Staphylococcus epidermidis. Moreover, the antibacterial efficacy of NIC-loaded catheters was validated in an in vivo biomaterial-associated infection model using a methicillin-susceptible and methicillin-resistant strain of S. aureus. The released NIC from the produced catheters reduced bacterial colonization of the catheter as well as of the surrounding tissue. In summary, the NIC-releasing hot-melt extruded catheters prevented implant colonization and reduced the bacterial colonization of peri-catheter tissue by methicillin sensitive as well as resistant S. aureus in a biomaterial-associated infection mouse model and has good prospects for preclinical development.
Identifiants
pubmed: 35854044
doi: 10.1038/s41598-022-16107-4
pii: 10.1038/s41598-022-16107-4
pmc: PMC9296466
doi:
Substances chimiques
Anti-Bacterial Agents
0
Biocompatible Materials
0
Polyurethanes
0
Niclosamide
8KK8CQ2K8G
Methicillin
Q91FH1328A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12329Subventions
Organisme : Marie Curie
ID : 722467
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
French, P., Tanase, D. & Goosen, J. Sensors for catheter applications. Sensors Update 13, 107–153 (2003).
doi: 10.1002/seup.200390018
O’grady, N. P. et al. Guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 35, 1281–1307 (2002).
doi: 10.1086/344188
Dudeck, M. A. et al. National Healthcare Safety Network (NHSN) Report, data summary for 2010, device-associated module. Am. J. Infect. Control 39, 798 (2011).
pubmed: 22133532
doi: 10.1016/j.ajic.2011.10.001
Lee, Y.-M. et al. Clinical impact of early reinsertion of a central venous catheter after catheter removal in patients with catheter-related bloodstream infections. Infect. Control Hosp. Epidemiol. 42, 162–168 (2021).
pubmed: 32900398
doi: 10.1017/ice.2020.405
O’Grady, N. P. & Kadri, S. S. Central venous catheter failures: Nowhere near zero. Crit. Care Med. 46, 2054 (2018).
pubmed: 30444813
pmcid: 6241295
doi: 10.1097/CCM.0000000000003479
Katneni, R. & Hedayati, S. S. Central venous catheter-related bacteremia in chronic hemodialysis patients: Epidemiology and evidence-based management. Nat. Clin. Pract. Nephrol. 3, 256–266 (2007).
pubmed: 17457359
doi: 10.1038/ncpneph0447
Mah, T.-F.C. & O’Toole, G. A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34–39 (2001).
pubmed: 11166241
doi: 10.1016/S0966-842X(00)01913-2
Arciola, C. R., Campoccia, D. & Montanaro, L. Implant infections: Adhesion, biofilm formation and immune evasion. Nat. Rev. Microbiol. 16, 397 (2018).
pubmed: 29720707
doi: 10.1038/s41579-018-0019-y
Saint, S., Veenstra, D. L. & Lipsky, B. A. The clinical and economic consequences of nosocomial central venous catheter-related infection: Are antimicrobial catheters useful?. Infect. Control Hosp. Epidemiol. 21, 375–380 (2000).
pubmed: 10879567
doi: 10.1086/501776
Zander, Z. K. & Becker, M. L. Antimicrobial and Antifouling Strategies for Polymeric Medical Devices (ACS Publications, 2018).
doi: 10.1021/acsmacrolett.7b00879
Farha, M. A. & Brown, E. D. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4, 565–577 (2019).
pubmed: 30833727
doi: 10.1038/s41564-019-0357-1
Organization WH. World Health Organization Model List of Essential Medicines: 21st List 2019 (World Health Organization, 2019).
Rajamuthiah, R. et al. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS ONE 10, e0124595 (2015).
pubmed: 25897961
pmcid: 4405337
doi: 10.1371/journal.pone.0124595
Gwisai, T. et al. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. Biomed. Mater. 12, 045010 (2017).
pubmed: 28471351
pmcid: 5730268
doi: 10.1088/1748-605X/aa7105
Brunaugh, A. D. et al. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLoS ONE 16, e0246803 (2021).
pubmed: 33571320
pmcid: 7877651
doi: 10.1371/journal.pone.0246803
Xu, J. et al. Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. Bioorg. Med. Chem. Lett. 29, 1399–1402 (2019).
pubmed: 30954430
doi: 10.1016/j.bmcl.2019.03.032
Das, S., Dasgupta, A. & Chopra, S. Drug repurposing: A new front in the war against Staphylococcus aureus. Future Microbiol. 11, 1091–1099 (2016).
pubmed: 27494302
doi: 10.2217/fmb-2016-0021
Torres, N. S. et al. Screening a commercial library of pharmacologically active small molecules against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 60, 5663–5672 (2016).
pubmed: 27401577
pmcid: 5038268
doi: 10.1128/AAC.00377-16
Zhurina, M. et al. Niclosamide as a promising antibiofilm agent. Microbiology 86, 455–462 (2017).
doi: 10.1134/S0026261717040154
Gilbert-Girard, S., Savijoki, K., Yli-Kauhaluoma, J. & Fallarero, A. Optimization of a high-throughput 384-well plate-based screening platform with Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 15442 biofilms. Int. J. Mol. Sci. 21, 3034 (2020).
pmcid: 7246797
doi: 10.3390/ijms21093034
Whitesell, J. K. The Merck Index, CD-ROM (Macintosh): an encyclopedia of chemicals, drugs & biologicals. (eds Budavari, S. et al.) (Merck & Co., Inc., Chapman & Hall, 1997) $250.00. ISBN 0-412-75940-3 (1998).
Chen, W., Mook, R. A. Jr., Premont, R. T. & Wang, J. Niclosamide: Beyond an antihelminthic drug. Cell. Signal. 41, 89–96 (2018).
pubmed: 28389414
doi: 10.1016/j.cellsig.2017.04.001
Kadri, H., Lambourne, O. A. & Mehellou, Y. Niclosamide, a drug with many (re)purposes. ChemMedChem 13, 1088–1091 (2018).
pubmed: 29603892
pmcid: 7162286
doi: 10.1002/cmdc.201800100
Tharmalingam, N., Port, J., Castillo, D. & Mylonakis, E. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Sci. Rep. 8, 3701 (2018).
pubmed: 29487357
pmcid: 5829259
doi: 10.1038/s41598-018-22037-x
Mohammad, H., AbdelKhalek, A., Abutaleb, N. S. & Seleem, M. N. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. Int. J. Antimicrob. Agents 51, 897–904 (2018).
pubmed: 29432868
pmcid: 5988938
doi: 10.1016/j.ijantimicag.2018.02.003
Domalaon, R., De Silva, P. M., Kumar, A., Zhanel, G. G. & Schweizer, F. The anthelmintic drug niclosamide synergizes with colistin and reverses colistin resistance in Gram-negative bacilli. Antimicrob. Agents Chemother. 63, e02574-18 (2019).
pubmed: 30917988
pmcid: 6437516
doi: 10.1128/AAC.02574-18
Copp, J. N. et al. Mechanistic understanding enables the rational design of salicylanilide combination therapies for Gram-negative infections. MBio 11, e02068-20 (2020).
pubmed: 32934086
pmcid: 7492738
doi: 10.1128/mBio.02068-20
Verstraete, G. et al. Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis. Int. J. Pharm. 529, 218–226 (2017).
pubmed: 28663088
doi: 10.1016/j.ijpharm.2017.06.076
Shaqour, B. et al. Coupling additive manufacturing with hot melt extrusion technologies to validate a ventilator-associated pneumonia mouse model. Pharmaceutics 13, 772 (2021).
pubmed: 34064276
pmcid: 8224298
doi: 10.3390/pharmaceutics13060772
Shaqour, B. et al. Novel design for an additively manufactured nozzle to produce tubular scaffolds via fused filament fabrication. Addit. Manuf. 49, 102467 (2021).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
pubmed: 22930834
pmcid: 5554542
doi: 10.1038/nmeth.2089
ISO IJISG, Switzerland. 527–1: 2019 Plastics-Determination of Tensile Properties-Part 1: General Principles. 1–26 (2019).
Kapale, S. S. & Chaudhari, H. K. Niclosamide & challenges in chemical modifications: A broad review on enhancement of solubility. J. Indian Chem. Soc. 98, 100262 (2021).
doi: 10.1016/j.jics.2021.100262
Pardhi, V. et al. Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems. Int. J. Pharm. 528, 202–214 (2017).
pubmed: 28596138
doi: 10.1016/j.ijpharm.2017.06.007
Sabee MM, Awang M, Bustami Y, Hamid ZA. Gentamicin loaded PLA microspheres susceptibility against Staphylococcus aureus and Escherichia coli by Kirby-Bauer and micro-dilution methods. In AIP Conference Proceedings). AIP Publishing LLC (2020).
Weinstein, M. P. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. M07 11th edn. (Clinical and Laboratoy Standards Institute, 2018).
Mandel, S. et al. OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria. Sci. Rep. 11, 6603 (2021).
pubmed: 33758343
pmcid: 7988117
doi: 10.1038/s41598-021-86155-9
Law, K.-Y. Definitions for hydrophilicity, hydrophobicity, and superhydrophobicity: Getting the basics right. J. Phys. Chem. Lett. 5, 686–688 (2014).
pubmed: 26270837
doi: 10.1021/jz402762h
Naqvi, S., Mohiyuddin, S. & Gopinath, P. Niclosamide loaded biodegradable chitosan nanocargoes: An in vitro study for potential application in cancer therapy. R. Soc. Open Sci. 4, 170611 (2017).
pubmed: 29291056
pmcid: 5717630
doi: 10.1098/rsos.170611
Mathew, E. et al. Fused deposition modeling as an effective tool for anti-infective dialysis catheter fabrication. ACS Biomater. Sci. Eng. 5, 6300–6310 (2019).
pubmed: 33405537
doi: 10.1021/acsbiomaterials.9b01185
Zaazaa, H. E., Abdelrahman, M. M., Ali, N. W., Magdy, M. A. & Abdelkawy, M. Kinetic study and mechanism of Niclosamide degradation. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 132, 655–662 (2014).
doi: 10.1016/j.saa.2014.04.050
Jiang, L. et al. Electrospun nanofibrous thermoplastic polyurethane/poly (glycerol sebacate) hybrid scaffolds for vocal fold tissue engineering applications. Mater. Sci. Eng., C 94, 740–749 (2019).
doi: 10.1016/j.msec.2018.10.027
Zhang, S. & Ma, J. Study on the unsaturated hydrogen bond behavior of bio-based polyamide 56. E-Polymers 19, 23–31 (2019).
doi: 10.1515/epoly-2019-0004
Sanphui, P., Kumar, S. S. & Nangia, A. Pharmaceutical cocrystals of niclosamide. Cryst. Growth Des. 12, 4588–4599 (2012).
doi: 10.1021/cg300784v
Witzleben, S. T., Walbrueck, K., Klein, S. E. & Schulze, M. Investigation of temperature dependency of morphological properties of thermoplastic polyurethane using WAXS and SAXS monitoring. (2015).
Jara, M. O., Warnken, Z. N. & Williams, R. O. Amorphous solid dispersions and the contribution of nanoparticles to in vitro dissolution and in vivo testing: Niclosamide as a case study. Pharmaceutics 13, 97 (2021).
pubmed: 33466598
pmcid: 7828663
doi: 10.3390/pharmaceutics13010097
Cho, S., Lee, E., Jo, S., Kim, G. M. & Kim, W. Extrusion characteristics of thin walled tubes for catheters using thermoplastic elastomer. Polymers 12, 1628 (2020).
pmcid: 7464286
doi: 10.3390/polym12081628
Shaqour, B. et al. Production of drug delivery systems using fused filament fabrication: A systematic review. Pharmaceutics 12, 517 (2020).
pmcid: 7356885
doi: 10.3390/pharmaceutics12060517
Organization WH. Antimicrobial Resistance: Global Report on Surveillance (World Health Organization, 2014).
Chang, Y-W., Yeh, T-K., Lin, K-T., Chen, W-C. & Yao, H-T. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Anal. 14, (2006).
Barbosa, E. J., Löbenberg, R., de Araujo, G. L. B. & Bou-Chacra, N. A. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. Eur. J. Pharm. Biopharm. 141, 58–69 (2019).
pubmed: 31078739
doi: 10.1016/j.ejpb.2019.05.004
Backer, V. et al. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. Lancet Reg. Health-Eur. 4, 100084 (2021).
pubmed: 33842908
pmcid: 8021896
doi: 10.1016/j.lanepe.2021.100084
Parikh, M. et al. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci. Rep. 11, 1–7 (2021).
doi: 10.1038/s41598-021-85969-x
Hamdoun, S., Jung, P. & Efferth, T. Drug repurposing of the anthelmintic niclosamide to treat multidrug-resistant leukemia. Front. Pharmacol. 8, 110–110 (2017).
pubmed: 28344555
pmcid: 5344920
doi: 10.3389/fphar.2017.00110
Zhang, J. L. et al. New life for an old drug: in vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strain. Int. J. Parasitol. Drugs Drug Resist. 9, 27–34 (2019).
pubmed: 30599391
doi: 10.1016/j.ijpddr.2018.12.004
Brunaugh, A. D. et al. Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models. BioRxiv (2020).
Jara, M. O. et al. Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters. Int. J. Pharm. 603, 120701 (2021).
pubmed: 33989748
pmcid: 8112893
doi: 10.1016/j.ijpharm.2021.120701
Lin, C.-K. et al. Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. Oncotarget 7, 8993 (2016).
pubmed: 26848771
pmcid: 4891020
doi: 10.18632/oncotarget.7113
Nofar, M., Mohammadi, M. & Carreau, P. J. Effect of TPU hard segment content on the rheological and mechanical properties of PLA/TPU blends. J. Appl. Polym. Sci. 137, 49387 (2020).
doi: 10.1002/app.49387
Kowalczuk, D. & Pitucha, M. Application of FTIR method for the assessment of immobilization of active substances in the matrix of biomedical materials. Materials 12, 2972 (2019).
pmcid: 6766236
doi: 10.3390/ma12182972
Kowalczuk, D. FTIR characterization of the development of antimicrobial catheter coatings loaded with fluoroquinolones. Coatings 10, 818 (2020).
doi: 10.3390/coatings10090818
Baghel, S., Cathcart, H. & O’Reilly, N. J. Polymeric amorphous solid dispersions: A review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J. Pharm. Sci. 105, 2527–2544 (2016).
pubmed: 26886314
doi: 10.1016/j.xphs.2015.10.008
Stewart, S. A., Domínguez-Robles, J., Donnelly, R. F. & Larrañeta, E. Implantable polymeric drug delivery devices: Classification, manufacture, materials, and clinical applications. Polymers 10, 1379 (2018).
pmcid: 6401754
doi: 10.3390/polym10121379
Pillai, O. & Panchagnula, R. Polymers in drug delivery. Curr. Opin. Chem. Biol. 5, 447–451 (2001).
pubmed: 11470609
doi: 10.1016/S1367-5931(00)00227-1
Amin Yavari, S., Castenmiller, S. M., van Strijp, J. A. & Croes, M. Combating implant infections: Shifting focus from bacteria to host. Adv. Mater. 32, 2002962 (2020).
doi: 10.1002/adma.202002962
Lau, Q. Y. et al. An FDA-drug library screen for compounds with bioactivities against meticillin-resistant Staphylococcus aureus (MRSA). Antibiotics 4, 424–434 (2015).
pubmed: 27025633
pmcid: 4790305
doi: 10.3390/antibiotics4040424
Nowakowska, J., Landmann, R. & Khanna, N. Foreign body infection models to study host-pathogen response and antimicrobial tolerance of bacterial biofilm. Antibiotics 3, 378–397 (2014).
pubmed: 27025752
pmcid: 4790362
doi: 10.3390/antibiotics3030378
Copp, J. N. et al. Mechanistic understanding enables the rational design of salicylanilide combination therapies for Gram-negative infections. MBio 11, e02068-02020 (2020).
doi: 10.1128/mBio.02068-20
Zaat, S. A. J., Broekhuizen, C. A. N. & Riool, M. Host tissue as a niche for biomaterial-associated infection. Future Microbiol. 5, 1149–1151 (2010).
pubmed: 20722591
doi: 10.2217/fmb.10.89
Zaat, S. A. J. Tissue colonization in biomaterial-associated infection. In Biomaterials Associated Infection (Springer, 2013).
Mermel, L. A. What is the predominant source of intravascular catheter infections?. Clin. Infect. Dis. 52, 211–212 (2011).
pubmed: 21288845
doi: 10.1093/cid/ciq108
Casimero, C. et al. Minimising blood stream infection: Developing new materials for intravascular catheters. Medicines 7, 49 (2020).
pmcid: 7554993
doi: 10.3390/medicines7090049
Zhang, D. et al. Drug concentration asymmetry in tissues and plasma for small molecule–related therapeutic modalities. Drug Metab. Dispos. 47, 1122–1135 (2019).
pubmed: 31266753
pmcid: 6756291
doi: 10.1124/dmd.119.086744
Thatikonda, S., Pooladanda, V. & Godugu, C. Repurposing an old drug for new use: Niclosamide in psoriasis-like skin inflammation. J. Cell. Physiol. 235, 5270–5283 (2020).
pubmed: 31846070
doi: 10.1002/jcp.29413
Boyapally, R., Pulivendala, G., Bale, S. & Godugu, C. Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins & Wnt/β-catenin signaling: A drug repurposing study. Life Sci. 220, 8–20 (2019).
pubmed: 30611787
doi: 10.1016/j.lfs.2018.12.061
Liang, L. et al. Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm. Res. 64, 225–233 (2015).
pubmed: 25708600
doi: 10.1007/s00011-015-0801-5
Londoño-Joshi, A. I. et al. Effect of niclosamide on basal-like breast cancers. Mol. Cancer. Ther. 13, 800–811 (2014).
pubmed: 24552774
pmcid: 3981919
doi: 10.1158/1535-7163.MCT-13-0555
Zhu, Y. et al. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. Biochem. Pharmacol. 169, 113610 (2019).
pubmed: 31465777
doi: 10.1016/j.bcp.2019.08.012
Hayes, W. J. & Laws, E. R. Handbook of Pesticide Toxicology (1991).
World Health Organization. WHO Specifications and Evaluations for Public Health Pesticides: Niclosamide (2002).